Page 3 - Granules India

Derivatives analyst Nandish Shah recommends Bull Spread on Granules India

The analyst from HDFC Securities recommends buying Granules India 320 Call and simultaneously selling 340 Call of the September series.

Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India

Brokerage house Centrum Broking has given a 'buy' call for Vijaya Diagnostic Centre and Granules India stocks

Granules India, IOL Chemicals hit 52-week lows on weak Q2 results

IOL Chemicals slipped 10% to Rs 487, while Granules was down 8% to 285.80 on the BSE in intra-day trade

Drug firms Granules India, Jubilant Cadista recall products in US market

Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.

Drug firm Granules India Q1 consolidated net profit up 8% to Rs 120 cr

Drug firm Granules India on Tuesday reported an 8 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 30, 2021.

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

The stock of Tata Chemicals has maintained a good support base near Rs 690 levels and picked up momentum currently

Granules India surges 6% on Carlyle group acquisition buzz

Carlyle is expected to buy 42 per cent of promoter shares, which will trigger an open offer to acquire additional stake from others, CNBC TV18 report.

Granules India shares gain 5%, hit record high on heavy volumes

In Q2FY21, the company's Ebitda grew 78.6 per cent YoY, with a 935 basis points margin expansion YoY on changing product mix and improved operational efficiencies

Granules India gets USFDA approval for potassium chloride tablets

Drug firm Granules India said it has received marketing approval from the US health regulator for Potassium Chloride extended release tablets, used for treatment of patients with hypokalemia

MARKET WRAP: Sensex surges 835 pts, Nifty reclaims 11K; Nifty IT up over 3%

All that happened in the markets today

Granules India up 5% on USFDA approval for generic Aleve PM tablets

According to media reports, global private equity firms have expressed interest in acquiring a controlling stake in the company

Granules shares rise 5% on US FDA nod for ADHD treatment drug

The stock has rallied 86 per cent in the past three months as compared to 13.5 per cent rise in the S&P BSE Sensex

Granules India hits fresh record high of Rs 384; rallies 24% in 2 weeks

Analysts expect launches in formulations and additional capacity in pharmaceutical formulation intermediate (PFIs) to be key growth drivers

Granules India rallies 8% in a weak market, hits fresh all-time high

The stock hit a record high of Rs 350 today. It has surged 13% thus far in the current week, as compared to a 2% decline in the S&P BSE Sensex

Lupin, Granules India recall 971,000 diabetes drug bottles from US market

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

RIL hits Rs 2000 mark; Muthoot Finance, Laurus Labs hit record high

RIL hit a fresh record high of Rs 2,000 mark, up 1.4 per cent in intra-day trade today.

Granules India surges 8%, hits new high on strong June quarter results

In Q1FY21, Granules India's Ebitda margin improved 503 basis points to 25 per cent

Pharma shares gain; Biocon, Granules hit record highs, Sun Pharma up 3%

At 10:27 am, Nifty Pharma index was up 1.5 per cent, as compared to 0.22 per cent decline in the benchmark Nifty50 index

Granules India surges 7%, hits record high on heavy volumes

The trading volumes on the counter more-than-doubled with a combined 6.6 million shares changing hands on the NSE and BSE till 02:43 pm

Granules India gets tentative USFDA nod for Colchicine capsules for gout

The USFDA has tentatively approved the abbreviated new drug application filed by Granules Pharmaceuticals for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to BSE.